Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:01 PM
Ignite Modification Date:
2025-12-24 @ 2:01 PM
NCT ID:
NCT00004695
Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
Documented common variable immunodeficiency defined as a reduction of serum IgG by at least 2 standard deviations
In vitro lymphocyte proliferative response to PEG-IL-2 of at least 10 times more than unstimulated cultures
--Prior/Concurrent Therapy--
No biologic response modifier therapy (i.e., interferon, cyclosporin A) except prednisone (maximum 10 mg/day)
Concurrent treatment with same dosage intravenous gamma-globulin for at least 6 months is required
--Patient Characteristics--
Life expectancy: At least 24 months
Other: Not pregnant or nursing HIV negative
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
2 Years
Study:
NCT00004695
Study Brief:
Protocol Section:
NCT00004695